Skip to main content
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 53
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Audisio, Riccardo A. Icardi, Giancarlo Isidori, Andrea M. Liverani, Carlo A. Lombardi, Alberto Mariani, Luciano Mennini, Francesco Saverio Mitchell, David A. Peracino, Andrea Pecorelli, Sergio Rezza, Giovanni Signorelli, Carlo Rosati, Giovanni Vitali and Zuccotti, Gian Vincenzo 2016. Public health value of universal HPV vaccination. Critical Reviews in Oncology/Hematology, Vol. 97, p. 157.

    Gibson, Edward Begum, Najida Sigmundsson, Birgir Sackeyfio, Alfred Hackett, Judith and Rajaram, Sankarasubramanian 2016. Economic evaluation of pediatric influenza immunization program compared with other pediatric immunization programs: A systematic review. Human Vaccines & Immunotherapeutics, Vol. 12, Issue. 5, p. 1202.

    Herdman, Michael Cole, Amanda Hoyle, Christopher K. Coles, Victoria Carroll, Stuart and Devlin, Nancy 2016. Sources and Characteristics of Utility Weights for Economic Evaluation of Pediatric Vaccines: A Systematic Review. Value in Health, Vol. 19, Issue. 2, p. 255.

    Estela Cubells, José Ramón 2015. Impacto de la vacunación en la incidencia de condilomas acuminados. Piel, Vol. 30, Issue. 4, p. 209.

    Jit, Mark and Mibei, Walter 2015. Discounting in the evaluation of the cost-effectiveness of a vaccination programme: A critical review. Vaccine, Vol. 33, Issue. 32, p. 3788.

    Nghiem, V T Davies, K R Beck, J R Follen, M MacAulay, C Guillaud, M and Cantor, S B 2015. Economic evaluation of DNA ploidy analysis vs liquid-based cytology for cervical screening. British Journal of Cancer, Vol. 112, Issue. 12, p. 1951.

    Simonella, Leonardo and Canfell, Karen 2015. Development of a quality framework for models of cervical screening and its application to evaluations of the cost-effectiveness of HPV vaccination in developed countries. Vaccine, Vol. 33, Issue. 1, p. 34.

    Abogunrin, Seye Di Tanna, Gian Luca Keeping, Sam Carroll, Stuart and Iheanacho, Ike 2014. Prevalence of human papillomavirus in head and neck cancers in European populations: a meta-analysis. BMC Cancer, Vol. 14, Issue. 1,

    Bernáldez, Javier Padilla 2014. Actualización en el virus del papiloma humano. FMC - Formación Médica Continuada en Atención Primaria, Vol. 21, Issue. 2, p. 67.

    McCormack, Paul L. 2014. Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®): A Review of Its Use in the Prevention of Premalignant Anogenital Lesions, Cervical and Anal Cancers, and Genital Warts. Drugs, Vol. 74, Issue. 11, p. 1253.

    Ramos-Barrón, M.Á. Vázquez-Rodríguez, J.A. and García-Garrido, A.B. 2014. Análisis coste-beneficio de un programa poblacional de diagnóstico precoz de cáncer de cuello uterino diseñado para Cantabria. SEMERGEN - Medicina de Familia, Vol. 40, Issue. 6, p. 296.

    Bertaut, Aurélie Chavanet, Pascal Aho, Serge Astruc, Karine Douvier, Serge and Fournel, Isabelle 2013. HPV vaccination coverage in French girls attending middle and high schools: a declarative cross sectional study in the department of Côte d’Or. European Journal of Obstetrics & Gynecology and Reproductive Biology, Vol. 170, Issue. 2, p. 526.

    Bresse, Xavier Adam, Marjorie Largeron, Nathalie Roze, Stephane and Marty, Rémi 2013. A comparative analysis of the epidemiological impact and disease cost-savings of HPV vaccines in France. Human Vaccines & Immunotherapeutics, Vol. 9, Issue. 4, p. 823.

    Wade, R Spackman, E Corbett, M Walker, S Light, K Naik, R Sculpher, M and Eastwood, A 2013. Adjunctive colposcopy technologies for examination of the uterine cervix – DySIS, LuViva Advanced Cervical Scan and Niris Imaging System: a systematic review and economic evaluation. Health Technology Assessment, Vol. 17, Issue. 8, p. i.

    Raymakers, Adam J.N. Sadatsafavi, Mohsen Marra, Fawziah and Marra, Carlo A. 2012. Economic and Humanistic Burden of External Genital Warts. PharmacoEconomics, Vol. 30, Issue. 1, p. 1.

    Vokó, Zoltán Nagyjánosi, László and Kaló, Zoltán 2012. Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary. BMC Public Health, Vol. 12, Issue. 1,

    Chen, Meng-Kan Hung, Hui-Fang Duffy, Stephen Yen, Amy Ming-Fang and Chen, Hsiu-Hsi 2011. Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination. Journal of Evaluation in Clinical Practice, Vol. 17, Issue. 6, p. 1050.

    Demarteau, Nadia Detournay, Bruno Tehard, Bertrand El Hasnaoui, Abdelkader and Standaert, Baudouin 2011. A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer. International Journal of Public Health, Vol. 56, Issue. 2, p. 153.

    Fagot, Jean-Paul Boutrelle, Aurélie Ricordeau, Philippe Weill, Alain and Allemand, Hubert 2011. HPV vaccination in France: Uptake, costs and issues for the National Health Insurance. Vaccine, Vol. 29, Issue. 19, p. 3610.

    Koleva, Daniela De Compadri, Paola Padula, Anna and Garattini, Livio 2011. Economic evaluation of human papilloma virus vaccination in the European Union: a critical review. Internal and Emergency Medicine, Vol. 6, Issue. 2, p. 163.

  • International Journal of Technology Assessment in Health Care, Volume 24, Issue 1
  • January 2008, pp. 10-19

Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France

  • Christine Bergeron (a1), Nathalie Largeron (a2), Ruth McAllister (a3), Patrice Mathevet (a4) and Vanessa Remy (a2)
  • DOI:
  • Published online: 01 January 2008

Objectives: A vaccine to prevent diseases due to human papillomavirus (HPV) types 6, 11, 16, and 18 is now available in France. The objective of this study was to assess the health and economic impact in France of implementing a quadrivalent HPV vaccine alongside existing screening practices versus screening alone.

Methods: A Markov model of the natural history of HPV infection incorporating screening and vaccination, was adapted to the French context. A vaccine that would prevent 100 percent of HPV 6, 11, 16, and 18-associated diseases, with lifetime duration and 80 percent coverage, given to girls at age 14 in conjunction with current screening was compared with screening alone. Results were analyzed from both a direct healthcare cost perspective (DCP) and a third-party payer perspective (TPP). Indirect costs such as productivity loss were not taken into account in this analysis.

Results: The incremental cost per life-year gained from vaccination was €12,429 (TPP) and €20,455 (DCP). The incremental cost per quality-adjusted life-year (QALY) for the introduction of HPV vaccination alongside the French cervical cancer screening program was €8,408 (TPP) and €13,809 (DCP). Sensitivity analyses demonstrated that cost-effectiveness was stable, but was most sensitive to the discount rate used for costs and benefits.

Conclusions: Considering the commonly accepted threshold of €50,000 per QALY, these analyses support the fact that adding a quadrivalent HPV vaccine to the current screening program in France is a cost-effective strategy for reducing the burden of cervical cancer, precancerous lesions, and genital warts caused by HPV types 6, 11, 16, and 18.

Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

6.C Bergeron , JG Breugelmans , S Bouee , Cervical cancer screening and associated treatment costs in France. Gynecol Obstet Fertil. 2006;34:10361042.

7.L Bonneux , E Birnie . The discount rate in the economic evaluation of prevention: A thought experiment. J Epidemiol Community Health. 2001;55:123125.

8.JM Bos , MJ Postma , L Annemans . Discounting health effects in pharmacoeconomic evaluations: Current controversies. Pharmacoeconomics. 2005;23:639649.

9.F Bray , R Sankila , J Ferlay , Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer. 2002;38:99166.

10.K Canfell , R Barnabas , J Patnick , The predicted effect of changes in cervical screening practice in the UK: Results from a modelling study. Br J Cancer. 2004;91:530536.

11.GM Clifford , RK Rana , Franceschi S, et al. Human papillomavirus genotype distribution in low-grade cervical lesions: Comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:11571164.

12.GM Clifford , JS Smith , T Aguado , Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: A meta-analysis. Br J Cancer. 2003;89:101105.

14.EJ Dasbach , EH Elbasha , RP Insinga . Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev. 2006;28:88100.

15.EH Elbasha , EJ Dasbach , RP Insinga . Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007;13:2841.

20.SM Garland , M Hernandez-Avila , CM Wheeler , Quadrivalent vaccine against Human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:19281943.

21.SJ Goldie , M Kohli , D Grima , Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004;96:604615.

23.J Karnon , J Peters , J Platt , Liquid-based cytology in cervical screening: An updated rapid and systematic review and economic analysis. Health Technol Assess. 2004;8:iii, 1-iii,78.

24.L Koutsky . Epidemiology of genital human papillomavirus infection. Am J Med. 1997;102:38.

25.SL Kulasingam , ER Myers . Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA. 2003;290:781789.

33.MF Mitchell , D Schottenfeld , G Tortolero-Luna , Colposcopy for the diagnosis of squamous intraepithelial lesions: A meta-analysis. Obstet Gynecol. 1998;91:626631.

35.N Mubiayi , E Bogaert , F Boman , Cytological history of 148 women presenting with invasive cervical cancer. Gynecol Obstet Fertil. 2002;30:210217.

37.ER Myers , DC McCrory , K Nanda , Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol. 2000;151:11581171.

38.K Nanda , DC McCrory , ER Myers , Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: A systematic review. Ann Intern Med. 2000;132:810819.

40.SE Olsson , LL Villa , RLR Costa , Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine. 2007;25:49314939.

41.SR Pagliusi . Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine. 2004;23:569578.

45.GD Sanders , AV Taira . Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis. 2003;9:3748.

46.The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:19151927.

47.N Van de Velde , M Brisson , MC Boily . Modeling human papillomavirus vaccine effectiveness: Quantifying the impact of parameter uncertainty. Am J Epidemiol. 2007;165:762775.

48.LL Villa , RL Costa , C Petta , High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95:14591466.

50.JM Walboomers , MV Jacobs , MM Manos , Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:1219.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

International Journal of Technology Assessment in Health Care
  • ISSN: 0266-4623
  • EISSN: 1471-6348
  • URL: /core/journals/international-journal-of-technology-assessment-in-health-care
Please enter your name
Please enter a valid email address
Who would you like to send this to? *